Products

Comprehensive catalog of pharmaceutical solutions. Browse categories and send inquiries directly.

Connect With Us

All Products (882)

Quick filters: Solid Tumour Hematologic Both Name A-Z Name Z-A

Therapeutic Areas

Sort by

Molecule	Drug Class / Mechanism	Oncology Type
Niraparib	PARP Inhibitor	Solid Tumour
Molecule Niraparib Therapeutic Category Targeted Therapy Oncology Type Solid Tumour Drug Class / Mechanism PARP Inhibitor
Obatoclax	BCL-2 Inhibitor	Hematologic
Molecule Obatoclax Therapeutic Category Targeted Therapy Oncology Type Hematologic Drug Class / Mechanism BCL-2 Inhibitor
Obecabtagene Autoleucel	Chimeric Antigen Receptor T-Cell Therapy	Hematologic (Leukemia/Lymphoma/Myeloma)
Molecule Obecabtagene Autoleucel Therapeutic Category Cellular Therapy (CAR-T) Oncology Type Hematologic (Leukemia/Lymphoma/Myeloma) Drug Class / Mechanism Chimeric Antigen Receptor T-Cell Therapy
Obinutuzumab	Anti-CD20 mAb	Hematologic (Lymphoma/CLL)
Molecule Obinutuzumab Therapeutic Category Immunotherapy (Monoclonal Antibody) Oncology Type Hematologic (Lymphoma/CLL) Drug Class / Mechanism Anti-CD20 mAb
Obrindatamab	Bispecific T-Cell Engager	Both (Solid & Hematologic)
Molecule Obrindatamab Therapeutic Category Immunotherapy (Bispecific Antibody) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Bispecific T-Cell Engager
Ocaratuzumab	Anti-CD20 mAb	Hematologic (Lymphoma/CLL)
Molecule Ocaratuzumab Therapeutic Category Immunotherapy (Monoclonal Antibody) Oncology Type Hematologic (Lymphoma/CLL) Drug Class / Mechanism Anti-CD20 mAb
Odronextamab	Bispecific T-Cell Engager	Both (Solid & Hematologic)
Molecule Odronextamab Therapeutic Category Immunotherapy (Bispecific Antibody) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Bispecific T-Cell Engager
Ofatumumab	Anti-CD20 mAb	Hematologic (Lymphoma/CLL)
Molecule Ofatumumab Therapeutic Category Immunotherapy (Monoclonal Antibody) Oncology Type Hematologic (Lymphoma/CLL) Drug Class / Mechanism Anti-CD20 mAb
Olaratumab	PDGFR / GD2 Targeting Agent	Solid Tumour (Sarcoma/Neuroblastoma)
Molecule Olaratumab Therapeutic Category Targeted Therapy (Antibody) Oncology Type Solid Tumour (Sarcoma/Neuroblastoma) Drug Class / Mechanism PDGFR / GD2 Targeting Agent
Olomorasib	RET / MET / KRAS / IDH Inhibitor	Solid Tumour
Molecule Olomorasib Therapeutic Category Targeted Therapy Oncology Type Solid Tumour Drug Class / Mechanism RET / MET / KRAS / IDH Inhibitor
Olutasidenib	RET / MET / KRAS / IDH Inhibitor	Solid Tumour
Molecule Olutasidenib Therapeutic Category Targeted Therapy Oncology Type Solid Tumour Drug Class / Mechanism RET / MET / KRAS / IDH Inhibitor
Olverembatinib	BCR-ABL Tyrosine Kinase Inhibitor	Hematologic (Leukemia)
Molecule Olverembatinib Therapeutic Category Targeted Therapy Oncology Type Hematologic (Leukemia) Drug Class / Mechanism BCR-ABL Tyrosine Kinase Inhibitor

Niraparib Targeted Therapy
Therapeutic Category Targeted Therapy Oncology Type Solid Tumour Drug Class / Mechanism PARP Inhibitor
Obatoclax Targeted Therapy
Therapeutic Category Targeted Therapy Oncology Type Hematologic Drug Class / Mechanism BCL-2 Inhibitor
Obecabtagene Autoleucel Cellular Therapy (CAR-T)
Therapeutic Category Cellular Therapy (CAR-T) Oncology Type Hematologic (Leukemia/Lymphoma/Myeloma) Drug Class / Mechanism Chimeric Antigen Receptor T-Cell Therapy
Obinutuzumab Immunotherapy (Monoclonal Antibody)
Therapeutic Category Immunotherapy (Monoclonal Antibody) Oncology Type Hematologic (Lymphoma/CLL) Drug Class / Mechanism Anti-CD20 mAb
Obrindatamab Immunotherapy (Bispecific Antibody)
Therapeutic Category Immunotherapy (Bispecific Antibody) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Bispecific T-Cell Engager
Ocaratuzumab Immunotherapy (Monoclonal Antibody)
Therapeutic Category Immunotherapy (Monoclonal Antibody) Oncology Type Hematologic (Lymphoma/CLL) Drug Class / Mechanism Anti-CD20 mAb
Odronextamab Immunotherapy (Bispecific Antibody)
Therapeutic Category Immunotherapy (Bispecific Antibody) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Bispecific T-Cell Engager
Ofatumumab Immunotherapy (Monoclonal Antibody)
Therapeutic Category Immunotherapy (Monoclonal Antibody) Oncology Type Hematologic (Lymphoma/CLL) Drug Class / Mechanism Anti-CD20 mAb
Olaratumab Targeted Therapy (Antibody)
Therapeutic Category Targeted Therapy (Antibody) Oncology Type Solid Tumour (Sarcoma/Neuroblastoma) Drug Class / Mechanism PDGFR / GD2 Targeting Agent
Olomorasib Targeted Therapy
Therapeutic Category Targeted Therapy Oncology Type Solid Tumour Drug Class / Mechanism RET / MET / KRAS / IDH Inhibitor
Olutasidenib Targeted Therapy
Therapeutic Category Targeted Therapy Oncology Type Solid Tumour Drug Class / Mechanism RET / MET / KRAS / IDH Inhibitor
Olverembatinib Targeted Therapy
Therapeutic Category Targeted Therapy Oncology Type Hematologic (Leukemia) Drug Class / Mechanism BCR-ABL Tyrosine Kinase Inhibitor

‹ 1 … 48 49 50 51 52 … 74 ›

Product Range

Company

Global Network

Products

All Products (882)

Niraparib

Obatoclax

Obecabtagene Autoleucel

Obinutuzumab

Obrindatamab

Ocaratuzumab

Odronextamab

Ofatumumab

Olaratumab

Olomorasib

Olutasidenib

Olverembatinib

Niraparib

Obatoclax

Obecabtagene Autoleucel

Obinutuzumab

Obrindatamab

Ocaratuzumab

Odronextamab

Ofatumumab

Olaratumab

Olomorasib

Olutasidenib

Olverembatinib